Dr. Reddy’s Laboratories has reported a 1% drop in its profit after tax for the first quarter of the fiscal year 2022 (Q1 FY22) to INR 571 crores ($77 million), compared to INR 579 crores ($78 million) in the same quarter of the previous fiscal year. The Indian pharma giant had diluted earnings per share […]
Five Indian pharma companies – Cipla, Dr. Reddy’s Laboratories, Emcure Pharmaceuticals, Sun Pharmaceutical Industries, and Torrent Pharmaceuticals will join forces to undertake a clinical trial of Molnupiravir, an investigational oral anti-viral drug for the treatment of mild Covid-19 in India. The clinical trial of Molnupiravir will be in an outpatient setting. Molnupiravir is being developed […]
Dr. Reddy’s Laboratories has announced the commercial launch of the Defence Research and Development Organisation’s (DRDO) anti-Covid-19 drug 2-deoxy-D-glucose (2-DG). The Indian pharma giant said that it will supply the 2-DG drug to major government and private hospitals in India. In the initial weeks, Dr. Reddy’s Laboratories will make 2-DG available in hospitals in metros […]
Shilpa Medicare, through its fully-owned subsidiary Shilpa Biologicals, has signed a three-year agreement with Dr. Reddy’s Laboratories for the production and supply of the Sputnik V vaccine for Covid-19. The company will undertake production at its biologics research and development cum manufacturing center at Dharwad in Karnataka. Shilpa Medicare said that the targeted production of […]
Dr. Reddy’s Laboratories has launched the Sputnik V Covid vaccine in India with the first dose of the Russian vaccine administered today in Hyderabad. The soft launch of the Russian coronavirus vaccine follows the landing of the first batch of its imported doses in India earlier this month and the subsequent regulatory clearance from the […]
Dr. Reddy’s Laboratories said that it has forged a royalty-free, non-exclusive voluntary licensing agreement with US pharma giant Eli Lilly and Company (Lilly) for the manufacturing and commercialization of Covid-19 drug baricitinib in India. Baricitinib in combination with remdesivir had been given restricted emergency use approval by the Indian Central Drugs Standard Control Organization (CDSCO). […]
Dr. Reddy’s Laboratories has launched Ertapenem for Injection, 1 g/vial, a generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial, which has approval from the US Food and Drug Administration (FDA) for the treatment of various bacterial infections. The Indian pharma company has extended its partnership with Gland Pharma to launch Ertapenem for […]
Dr. Reddy’s Laboratories has launched Albendazole Tablets, USP, a generic version of GlaxoSmithKline’s Albenza Tablets, 200 mg, which are used for the treatment of a range of parasitic worm infestations. Approved by the US Food and Drug Administration (FDA), Albenza brand and generic had sales of around $27 million MAT for the most recent twelve […]
The Russian Direct Investment Fund (RDIF) has announced that the Sputnik V Covid-19 vaccine has been approved for use in India by the Drug Controller General of India (DCGI). India is now the 60th country to have approved the Sputnik V vaccine for giving protection against the novel coronavirus, said the Russian sovereign wealth fund. […]
Dr. Reddy’s Laboratories has secured permission from the Drug Controller General of India (DCGI) for importing the Sputnik V vaccine into India under emergency use authorization (EUA). In February 2021, Dr. Reddy’s Laboratories commenced the process to seek the emergency use authorization for the Russian Covid-19 vaccine from the Indian drug regulator. Last September 2020, […]